Halozyme Therapeutics (HALO) Says AbbVie (ABBV) Discontinued Development Using Halozyme ENHANZE

November 21, 2016 8:32 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie (NYSE: ABBV) has discontinued a development program using the Halozyme ENHANZEâ„¢ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target results were not achieved.

Halozyme and AbbVie will continue to work collaboratively to identify additional targets for co-development under their 2015 Global Collaboration and Licensing agreement. TNF-alpha was the first nominated target of nine included as part of the agreement.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Hot Corp. News, Trader Talk

Add Your Comment